Jundong Wu

5PUBLICATIONS
17CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 07, 2025
PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA.

Zhaochang Qi, Lifang He, Zemei Xu

|Aug 22, 2024
C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration.

Rongji Zheng, Tian Guan, Chaoqun Hong

|Feb 09, 2024
Prognostic implication of novel immune-related signature in breast cancer.

Bingfeng Chen, Haoming Wu, Yutong Fang

|Feb 09, 2024
HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.

Yutong Fang, Qunchen Zhang, Yuan Wu

|Mar 07, 2022
A Predictive Model for Nonsentinel Node Status after Sentinel Lymph Node Biopsy in Sentinel Lymph Node-Positive Chinese Women with Early Breast Cancer.

Lifang He, Peide Liang, Huancheng Zeng

Pageof 1

Frequent Collaborators

2 joint publications

Lifang He

1 joint publications

Peide Liang

1 joint publications

Huancheng Zeng

1 joint publications

Guangsheng Huang